Table 4.
Some considerations when choosing second‐ or third‐line systemic treatment for patients with advanced HCC in clinical practice
Second‐line treatment | Third‐line treatment | ||
---|---|---|---|
Sorafenib‐intolerant patients | Patients with low AFP | ||
Regorafenib | No | Yes | No |
Cabozantinib | Yes | Yes | Yes |
Ramuciramab | Yes | No | No |
Abbreviations: AFP, alpha‐fetoprotein; HCC, hepatocellular carcinoma.